Related Experiment Video

Updated: Aug 15, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

482

RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review

Tabrez Faruqui1, Mohd Sajid Khan2, Yusuf Akhter3

  • 1Department of Biosciences, Integral University, Dasauli, P.O. Basha, Kursi Road, Lucknow 226026, Uttar Pradesh, India.

International Journal of Molecular Sciences
|January 8, 2023
PubMed

Insights

The receptor for advanced glycation end products (RAGE) is overexpressed in cancers, promoting tumor growth and metastasis. Inhibiting RAGE-ligand interactions offers a promising strategy for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • The receptor for advanced glycation end products (RAGE) is an immunoglobulin family member implicated in cancer.
  • RAGE expression is elevated in various cancers, particularly in the lung, and correlates with inflammation.
  • RAGE binds diverse ligands, including advanced glycation end products and S100 proteins, mediating inflammatory and cellular stress responses.

Purpose of the Study:

  • To review the multifaceted roles of RAGE and its ligands in cancer pathogenesis.
  • To elucidate the significant involvement of RAGE in cancer development and progression.
  • To explore the therapeutic potential of targeting RAGE-ligand interactions.

Main Methods:

  • Literature review of studies investigating RAGE and its ligands in cancer.
  • Analysis of RAGE expression patterns in different cancer types.
  • Examination of signaling pathways initiated by RAGE activation.

Main Results:

  • RAGE acts as a critical signaling node, promoting carcinogenesis, tumor growth, and metastasis.
  • RAGE ligands contribute to cellular stress and growth signaling, driving cancer progression.
  • Evidence suggests RAGE is a key player in initiating and sustaining cancer development.

Conclusions:

  • Targeting the RAGE-ligand axis presents a viable therapeutic strategy for cancer.
  • Inhibiting RAGE interactions can potentially hinder cancer development and progression.
  • Further research into RAGE pathways may yield novel cancer treatments.
Keywords:
RAGERAGE inhibitorcancerend productstargeted therapy

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
621
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K